Real-world outcomes of patients with severe asthma treated with mepolizumab by baseline inhaled corticosteroid dose: Post hoc analysis of realiti-a at 2 years

被引：0
|
作者：
Smith, A. [1 ]
Patel, M. [1 ]
Caruso, C. [2 ]
Pilette, C. [3 ]
Welte, T. [4 ]
Alfonso-Cristancho, R. [5 ]
Price, R. G. [6 ]
Howarth, P. [7 ]
机构：
[1] Univ Hosp Wishaw, Wishaw, Scotland
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Clin Univ St Luc, Brussels, Belgium
[4] Hannover Med Sch, Hannover, Germany
[5] GSK, Collegeville, PA USA
[6] GSK, Stevenage, Herts, England
[7] GSK, Brentford, Middx, England
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000854
引用
收藏
页码：50 / 51
页数：2
相关论文
共 50 条
  • [41] Real-world clinical outcomes for patients in the UK with severe, atopic eosinophilic asthma treated with benralizumab
    Jackson, D. J.
    Dube, S.
    Morris, T.
    Burhan, H.
    Pfeffer, P.
    ALLERGY, 2020, 75 : 40 - 40
  • [42] Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy
    Fyles, Fred
    Nuttall, Amy
    Joplin, Hannah
    Burhan, Hassan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (09): : 2715 - 2723
  • [43] Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
    Barthwal, Madhusudan
    Dutta, Vijay
    Bhattacharya, Parthasarthi
    Vora, Agam
    Kotnis, Mangala
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [44] Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
    Charlene M. Prazma
    Elisabeth H. Bel
    Robert G. Price
    Eric S. Bradford
    Frank C. Albers
    Steven W. Yancey
    Respiratory Research, 20
  • [45] Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
    Prazma, Charlene M.
    Bel, Elisabeth H.
    Price, Robert G.
    Bradford, Eric S.
    Albers, Frank C.
    Yancey, Steven W.
    RESPIRATORY RESEARCH, 2019, 20 (1):
  • [46] Baseline characteristics of patients with severe eosinophilic asthma treated with benralizumab who reduced to anti-inflammatory reliever only vs high-, medium- or low- dose inhaled corticosteroid/formoterol: SHAMAL post-hoc analysis
    Kent, Brian
    Milger-Kneidinger, Katrin
    Heaney, Liam G.
    Menzies-Gow, Andrew
    Shavit, Anat
    Olinger, Lynda
    Jackson, David J.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [47] Treatment Outcomes During Brivaracetam Treatment by Seizure Freedom Status at Baseline: Post hoc Analysis of a Real-world, US Study
    Dave, Hina
    French, Jacqueline A.
    Henninger, Heidi
    Altalib, Hamada Hamid
    Porter, Roger
    Gelfand, Michael
    Martin, Melinda S.
    Dongre, Prashant
    Elmoufti, Sami
    Schulz, Anne-Liv
    Dimova, Svetlana
    Sperling, Michael R.
    NEUROLOGY, 2023, 100 (17)
  • [48] Real-world effectiveness of mepolizumab in patients with severe asthma with/without chronic rhinosinusitis with nasal polyps: pooled analysis from European cohorts
    Palomares, Ines
    Loukides, Stelios
    Schleich, Florence
    Chaudhuri, Rekha
    Leuppi, Joerg
    Heffler, Enrico
    Domingo, Cristian
    Micheletto, Claudio
    Paulsson, Thomas
    Gaw, Nina
    Kallinikou, Nadia
    Mcdermott, Eleanor
    Vossen, Carla
    Guelfucci, Florent
    Menon, Jyothi
    Ngami, Armel
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [49] Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma
    Chupp, Geoffrey
    Lee, Jason
    Liu, Mark
    Schleich, Florence
    Heaney, Liam
    Domingo Ribas, Christian
    Carrillo-Diaz, Teresa
    Blanco Aparicio, Marina
    Martinez Moragon, Eva
    Guadalupe Sanchez-Herrero, M.
    Gardiner, Frances
    Alfonso-Cristancho, Rafael
    Jakes, Rupert
    Price, Robert
    Howarth, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB318 - AB318
  • [50] An Add-on Reliever-Triggered Inhaled Corticosteroid Strategy Reduces Severe Asthma Exacerbations in a Real-World Study of African American/Black and Hispanic/Latinx Patients with Asthma
    Cardet, J. C.
    Pace, W. D.
    Carroll, J. K.
    Fuhlbrigge, A. L.
    She, L.
    Rockhold, F. W.
    Maher, N. E.
    Fagan, M.
    Forth, V. E.
    Hernandez, P. Arias
    Kruse, J.
    Manning, B. K.
    Rodriguez-Louis, J.
    Shields, J. B.
    Ericson, B.
    Colon-Moya, A. D.
    Coyne-Beasley, T.
    Hammer, G. M.
    Kaplan, B. M.
    Madison, S.
    Rand, C. S.
    Robles, J.
    Thompson, O.
    Wechsler, M. E.
    Wisnivesky, J. P.
    Mckee, M. D.
    Jariwala, S. P.
    Jerschow, E.
    Busse, P. J.
    Kaelber, D. C.
    Nazario, S.
    Hernandez, M. L.
    Apter, A. J.
    Chang, K.
    Pinto-Plata, V.
    Stranges, P. M.
    Hurley, L. H.
    Trevor, J.
    Casale, T. B.
    Chupp, G.
    Riley, I. L.
    Shenoy, K. V.
    Pasarica, M.
    Candelario, R. A. Calderon
    Tapp, H.
    Baydur, A.
    Yawn, B. P.
    Israel, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
12345